Menu Search
Equities

Haemonetics Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HAZ:MUN

Haemonetics Corp

Actions
  • Price (EUR)49.60
  • Today's Change0.00 / 0.00%
  • Shares traded1.00
  • 1 Year change-15.21%
  • Beta0.2775
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Haemonetics Corporation is a medical technology company. Its solutions address critical medical needs, which includes a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers, and products to enable blood centers to collect in-demand blood components. Its Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. Its Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies (Hemostasis Management, Cell Salvage and Transfusion Management products). It also offers solutions for structural heart and endovascular procedures.

  • Revenue in USD (TTM)1.32bn
  • Net income in USD175.44m
  • Incorporated1985
  • Employees3.02k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		HAE:NYQ since
announced		Transaction
value
Vivasure Medical LtdDeal completed09 Jan 202609 Jan 2026Deal completed-29.25%--
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.